Concepts (63)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 8 | 2025 | 1232 | 3.450 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2023 | 71 | 1.480 |
Why?
|
| Molecular Targeted Therapy | 2 | 2024 | 129 | 1.020 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2025 | 12 | 0.880 |
Why?
|
| Breast Neoplasms, Male | 1 | 2024 | 14 | 0.820 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 465 | 0.820 |
Why?
|
| Receptors, Estrogen | 1 | 2024 | 132 | 0.810 |
Why?
|
| Immunoconjugates | 1 | 2023 | 95 | 0.770 |
Why?
|
| BRCA2 Protein | 1 | 2022 | 20 | 0.740 |
Why?
|
| Febrile Neutropenia | 1 | 2021 | 6 | 0.680 |
Why?
|
| Frail Elderly | 1 | 2021 | 114 | 0.630 |
Why?
|
| Antineoplastic Agents | 2 | 2025 | 643 | 0.610 |
Why?
|
| Capecitabine | 1 | 2019 | 14 | 0.600 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 42 | 0.590 |
Why?
|
| Frailty | 1 | 2021 | 131 | 0.580 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2019 | 69 | 0.560 |
Why?
|
| Body Mass Index | 1 | 2021 | 899 | 0.510 |
Why?
|
| Female | 12 | 2025 | 34208 | 0.470 |
Why?
|
| Hospitalization | 1 | 2021 | 1402 | 0.400 |
Why?
|
| Neoadjuvant Therapy | 2 | 2023 | 102 | 0.370 |
Why?
|
| Disease Management | 2 | 2024 | 235 | 0.360 |
Why?
|
| Humans | 13 | 2025 | 65490 | 0.360 |
Why?
|
| Neoplasms | 1 | 2021 | 1372 | 0.320 |
Why?
|
| Prospective Studies | 2 | 2024 | 3325 | 0.220 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2024 | 38 | 0.210 |
Why?
|
| Receptors, Progesterone | 1 | 2024 | 112 | 0.210 |
Why?
|
| Survivorship | 1 | 2024 | 14 | 0.200 |
Why?
|
| Neoplasm Metastasis | 1 | 2024 | 223 | 0.200 |
Why?
|
| Mastectomy | 1 | 2024 | 56 | 0.200 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2023 | 92 | 0.190 |
Why?
|
| India | 1 | 2023 | 164 | 0.190 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2022 | 27 | 0.180 |
Why?
|
| Hemophilia A | 1 | 2022 | 57 | 0.180 |
Why?
|
| Treatment Outcome | 2 | 2024 | 5809 | 0.180 |
Why?
|
| BRCA1 Protein | 1 | 2022 | 70 | 0.180 |
Why?
|
| Germ Cells | 1 | 2022 | 120 | 0.170 |
Why?
|
| Neoplasm Staging | 1 | 2023 | 552 | 0.170 |
Why?
|
| Genetic Testing | 1 | 2022 | 142 | 0.170 |
Why?
|
| Antibodies, Bispecific | 1 | 2022 | 33 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 461 | 0.170 |
Why?
|
| Mammography | 1 | 2024 | 292 | 0.170 |
Why?
|
| Biomarkers, Tumor | 1 | 2024 | 526 | 0.170 |
Why?
|
| Patient Care Team | 1 | 2023 | 336 | 0.160 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 5649 | 0.160 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 326 | 0.150 |
Why?
|
| Retrospective Studies | 2 | 2023 | 6936 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 253 | 0.150 |
Why?
|
| Anus Neoplasms | 1 | 2019 | 25 | 0.150 |
Why?
|
| Chest Pain | 1 | 2019 | 86 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2023 | 769 | 0.140 |
Why?
|
| Inpatients | 1 | 2021 | 322 | 0.140 |
Why?
|
| Algorithms | 1 | 2023 | 1050 | 0.140 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 1115 | 0.130 |
Why?
|
| Middle Aged | 3 | 2024 | 18390 | 0.130 |
Why?
|
| Pregnancy | 1 | 2025 | 2392 | 0.130 |
Why?
|
| Cardiac Catheterization | 1 | 2019 | 292 | 0.130 |
Why?
|
| HIV Infections | 1 | 2022 | 957 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2021 | 2633 | 0.110 |
Why?
|
| Risk Assessment | 1 | 2021 | 2111 | 0.100 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 2724 | 0.100 |
Why?
|
| Male | 2 | 2024 | 31202 | 0.080 |
Why?
|
| Aged | 1 | 2021 | 15058 | 0.050 |
Why?
|
| Factor VIII | 1 | 2022 | 32 | 0.050 |
Why?
|